Dr. Mark McKenna is evolving his medical aesthetic business nationwide. This even though the noted doctor and entrepreneur opened only two brick-and-mortar boutiques.
The national reach is the result of an Uber-like app that connects providers of procedures like Botox nationwide with local clients. He told Forbes in an interview recently that clients can use the app to request home appointments.
For example, a medical aesthetic provider in a city like Chicago can log in and say they are available for the home Botox appointment. This, Dr. Adam McKenna continues, results in a lot of savings for the provider in that they do not have to pay overhead costs. The client can also use the app to order a virtual consult.
Atlanta-based Equity38 invested $4 million in the development of OVME app. The effort, according Dr. Mark McKenna’s Forbes interview, is a way of creating a brand identity around retail medical aesthetics, which he describes as a “very” fragmented industry.
A brick-and-mortar OVME boutique opened in Buckhead, GA, in early March, 2018. There is another location planned for Nashville. The doctor and entrepreneur said he wants to provide access to new, medical noninvasive treatments that go beyond a “one-size-fits-all” approach to aesthetics. Treatments, among others, include:
– Facial and skin services like Botox
– Male testosterone replacement
– PRP therapy for thinning hair
– Weight loss management programs
The aim is to take advantage of new technology and be on the forefront of change in the medical aesthetics industry, Dr. Mark McKenna told Patch.com in a press release.
Dr. Mark McKenna is a noted veteran of the medical aesthetic community and entrepreneur. His former business included ShapeMed, which he started in Atlanta in 2007 and grew to four locations. ShapeMed was sold in 2015 to Lifetime Fitness where he worked as the medical director briefly.
Prior to this, he was a doctor and real estate investor in New Orleans. After Hurricane Katrina, he sold his real estate stake and moved to Atlanta.
Amicus Therapeutics is a fifteen-year-old biopharmaceutical company specializing in rare and orphan diseases. Because of Amicus Therapeutics work with rare diseases they have received grants from The Michael J Fox Foundation & Alzheimer’s Drug Discovery Foundation. The public company’s focus at the moment is on a therapy for genetic diagnosis of Fabry disease. Fabry disease is rare and often misdiagnosed and is often found by symptoms of pain, kidney failure and cardiac complications. Amicus Therapeutics is also under development for a rare genetic connective tissue disorder called Epidermolysis Bullosa. This treatment named SD-101, at present, would be a first to market treatment for EB which can cause painful blisters and skin fragility.
Amicus Therapeutics and other innovative pharmaceutical companies like this will lead health care in the next decades. With more technology and understanding of disease and the body, there will be more opportunity for companies like Amicus Therapeutics to focus on unique market positions to be able to reach many Americans that are not being treated currently. Pain inducing diseases like Fabry disease are becoming more diagnosed as doctors begin to take pain seriously and look further than just pain management into the treatment of the causes of the pain. In 2008 the company expanded from a single New Jersey office, adding an office in San Diego as well. View the market summary of Amicus Therapeutics at finance.google.com.
Amicus Therapeutics expects further growth with the 2015 acquisition of Scioderm. The company’s commitment to innovation, smart risks, and the families and people that have these rare diseases will mean success for the company and the people that are counting Amicus Therapeutics to improve their everyday life. They are committed to being at the forefront of innovation in the development and research into therapies for rare diseases that often go unnoticed and under treated. They are dedicated to patients and families, and improving lives. Read the company profile at Crunchbase.